D2-Like Dopamine Receptor Neurons

📖 Wiki Page

cell833 wordssynced 2026-04-02

D2-Like Dopamine Receptor Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">D2-Like Dopamine Receptor Neurons</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Dopamine Receptor Neurons</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Striatum, VTA, PFC, Nucleus Accumbens</td>
</tr>
<tr>
<td class="label">Receptor Type</td>
<td>D2 (DRD2), D3 (DRD3), D4 (DRD4)</td>
</tr>
<tr>
<td class="label">Signaling</td>
<td>Gi-coupled, inhibitory</td>
</tr>
<tr>
<td class="label">Neurotransmitter</td>
<td>GABA (striatal), Dopamine (modulatory)</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Brain Region</td>
</tr>
<tr>
<td class="label">DRD2</td>
<td>Striatum</td>
</tr>
<tr>
<td class="label">DRD3</td>
<td>Limbic system</td>
</tr>
<tr>
<td class="label">DRD4</td>
<td>Cortex, hippocampus</td>
</tr>
</table>

...

D2-Like Dopamine Receptor Neurons

Introduction

D2-like dopamine receptor neurons express inhibitory dopamine receptors (DRD2, DRD3, DRD4) that mediate motor control, reward processing, and cognitive functions. These neurons are critically involved in Parkinson's disease (PD), Huntington's disease (HD), schizophrenia, and addiction. D2 receptor dysfunction is a hallmark of dopaminergic neurodegeneration[@beaulieu2011].

Overview

Mermaid diagram (expand to render)

Multi-Taxonomy Classification

Taxonomy Database Cross-References

External Database Links

[Cell Ontology (CL:0000197)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)
[OBO Foundry (CL:0000197)](http://purl.obolibrary.org/obo/CL_0000197)
[Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
[CellxGene Census](https://cellxgene.cziscience.com/)
[Human Cell Atlas](https://www.humancellatlas.org/)

Molecular Properties

Receptor Structure and Signaling

D2-like receptors share common structural features[@missale1998]:

Family: D2, D3, D4 dopamine receptors
G protein: Gi/o
Second messengers: Decreased cAMP, hyperpolarization
Ion channels: Activation of GIRK channels (Kir3.x)
Cellular effects: Inhibition of adenylate cyclase, reduced neuronal excitability

Receptor Distribution

Molecular Markers

Receptor proteins: DRD2, DRD3, DRD4
Effector proteins: DARPP-32, RGS9, β-arrestin
Channel proteins: GIRK2 (KCNJ6), GIRK3 (KCNJ9)
Enzymes: Adenylate cyclase 5 (ADCY5), phosphodiesterases

Normal Function

Motor Control

D2-expressing neurons in the striatum form the indirect pathway[@albin1989]:

Pathway activation: Cortex → striatopallidal neurons → GPi/SNr → thalamus

Movement suppression: Prevents unwanted movements

Action selection: Competes with direct pathway for motor control

Bradykinesia: D2 pathway overactivity contributes to parkinsonian akinesia

Reward Processing

D2 neurons encode reward prediction and motivation[@schultz1998]:

Reward prediction error: Phasic dopamine signals
Motivation: D2 receptor tone drives reward-seeking
Reinforcement: D2 activation reinforces behavioral patterns
Addiction: D2 receptor downregulation in substance abuse

Cognitive Functions

Prefrontal D2 receptors modulate working memory and attention[@goldmanrakic1994]:

Working memory: D2-mediated prefrontal cortical processing
Attention: Filtering of irrelevant stimuli
Decision-making: Risk-reward evaluation
Cognitive flexibility: Set-shifting abilities

Vulnerability in Neurodegeneration

Parkinson's Disease

D2 receptor neurons are central to PD pathophysiology[@kalia2015]:

D2 autoreceptor loss: Reduced feedback inhibition of dopamine neurons

Striatal D2 upregulation: Compensatory mechanism in early PD

D2/D3 signaling deficits: Impaired motor control

Levodopa-induced dyskinesia: D2 receptor hypersensitivity

Therapeutic implications:

Dopamine agonists (pramipexole, ropinirole) target D2/D3
D2 partial agonists (aripiprazole) in psychosis
Deep brain stimulation normalizes D2 pathway activity

Huntington's Disease

D2-expressing neurons are particularly vulnerable in HD[@glass2000]:

Selective striatal degeneration: Indirect pathway neurons degenerate early

D2 receptor loss: Progressive reduction in striatal D2 binding

Motor phenotype: Hyperkinetic movements from D2 pathway dysfunction

Cognitive decline: Prefrontal D2 dysfunction

Research findings:

PET imaging shows reduced D2 receptor binding in premanifest HD[@pavese2021]
Genetic deletion of D2 accelerates HD-like phenotypes in mice

Alzheimer's Disease

D2 receptor dysfunction contributes to AD symptoms[@martorana2014]:

Mesocortical dysfunction: Prefrontal D2 deficits in executive dysfunction

Reward deficits: Anhedonia in AD patients

Behavioral symptoms: Agitation, psychosis from dopaminergic dysfunction

Network disruption: Corticostriatal loop impairment

Schizophrenia

D2 receptor hyperactivity is a key feature of schizophrenia[@howes2012]:

D2 overexpression: Increased D2 receptor density

Signal transduction: Enhanced Gi-coupled inhibition

Therapeutic target: All antipsychotics block D2 receptors

Cognitive deficits: Prefrontal D2 dysfunction

Transcriptomic Profile

Single-cell RNA sequencing has characterized D2 neurons[@gokce2016]:

Marker genes:

DRD2, DRD3, DRD4 — dopamine receptors
PENK, PDYN — neuropeptide transmitters
ARPP21 — cAMP-regulated phosphoprotein

Disease-associated genes:

DRD2 — schizophrenia risk, Parkinson's response
DRD3 — Parkinson's dyskinesias, essential tremor
C9orf72 — ALS/FTD with dopaminergic involvement
HTT — Huntington's disease

Therapeutic Implications

Pharmacological Targets

D2 agonists: Pramipexole, ropinirole, rotigotine
D2 partial agonists: Aripiprazole, cariprazine
D2 antagonists: Haloperidol, risperidone (antipsychotics)
D3-selective agents: Selective D3 agonists for Parkinson's

Deep Brain Stimulation

STN-DBS: Normalizes indirect pathway activity
GPi-DBS: Reduces D2-mediated output
Effects on D2 signaling: Modulates receptor sensitivity

Gene Therapy

AAV-mediated D2 receptor delivery
CRISPR editing of D2 receptor variants
RNA targeting of D2 transcript
D1-Like Dopamine Receptor Neurons
Striatal Medium Spiny Neurons
[Parkinson's Disease](/diseases/parkinsons-disease)parkin)
[Huntington's Disease](/diseases/huntingtons)
[Alzheimer's Disease](/diseases/alzheimers-disease)
Dopamine Signaling Pathway
Basal Ganglia Circuitry

Background

The study of D2 Like Dopamine Receptor Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Pathway Diagram

The following diagram shows the key molecular relationships involving D2-Like Dopamine Receptor Neurons discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →